Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation. First clinical data supports imlifidase ability to substantially reduce antiAAV antibodies to allow administration of gene therapy. Lund, Sweden, 30 October 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced its interim report for January-September 2025. Read more…